J
Jedd D. Wolchok
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 795
Citations - 154490
Jedd D. Wolchok is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ipilimumab & Immune system. The author has an hindex of 140, co-authored 713 publications receiving 123336 citations. Previous affiliations of Jedd D. Wolchok include Ludwig Institute for Cancer Research & University of York.
Papers
More filters
Journal ArticleDOI
A Phase 2 Randomized Study of Ramucirumab (IMC 1121B; RAM) with or Without Dacarbazine (DTIC) in Patients (PTS) with Metastatic Melanoma (MM) (CP12-0604/NCT00533702)
Richard D. Carvajal,John A. Thompson,Michael S. Gordon,Karl D. Lewis,Anna C. Pavlick,Jedd D. Wolchok,P. Rojas,Jonathan D. Schwartz,Agop Y. Bedikian +8 more
TL;DR: RAM alone or in combination with DTIC was associated with acceptable incidence of AEs in MM, and clinical activity was modest on both arms.
Journal ArticleDOI
A phase II study of temozolomide (TMZ) and pegylated interferon {alpha}-2b (PGI) in the treatment of advanced melanoma
Susan E. Krown,W. Hwu,Jennifer H. Menell,K. S. Panageas,Lynne A. Lamb,S. Aird,Linda Williams,Paul B. Chapman,P. O. Livingston,Jedd D. Wolchok +9 more
TL;DR: The combination of TMZ with low-dose PGI is well tolerated and effective in patients with advanced melanoma without brain metastases and merits further study.
Journal ArticleDOI
Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma.
Michael B. Atkins,John M. Kirkwood,Jedd D. Wolchok,Margaret K. Callahan,Harriet M. Kluger,Michael A. Postow,Neil H. Segal,Alexander M. Lesokhin,Agnes Balogh,Sandra Re,Mario Sznol +10 more
TL;DR: A 3-year overall survival rate of 63% with NIVO+IPI concurrent therapy in the initial phase I dose-escalation study for the combination, conducted in pat...
Patent
Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
Michelle S. Bradbury,Michael Overholtzer,Cameron Brennan,Barney Yoo,Jedd D. Wolchok,Ulrich Wiesner +5 more
TL;DR: In this article, the authors describe methods of targeting tumor-associated macrophages, microglia, and/or other cells in a tumor microenvironment using such nanoparticle conjugates.
Journal ArticleDOI
Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
N. Yang,Aitor Benedicto Garcia,Cindy Meyer,Thomas Tuschl,Taha Merghoub,Jedd D. Wolchok,Liang Deng +6 more
TL;DR: In this paper , the authors explored the potential of heat-inactivated MVA (heat-iMVA) as a vaccine adjuvant for subunit vaccines against cancer or SARS-CoV-2.